CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $23.95, but opened at $28.2350. CSL shares last traded at $27.99, with a volume of 37,269 shares trading hands.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on CSLLY shares. Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Canaccord Genuity Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group downgraded CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Five research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold”.
CSL Price Performance
About CSL
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.
Further Reading
- Five stocks we like better than CSL
- Berkshire Just Made a Huge Alphabet Bet—Should You Follow?
- Michael Burry Is Betting Against Palantir Again—Should Investors Care?
- Fabrinet’s Sell-Off May Prove It Is One of AI’s Most Misunderstood Stocks
- Orbiting Wealth: Institutions Load Up SpaceX
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
